Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Jonathan Fuchs, MD, MPH
San Francisco Department of Public Health, University of California, San Francisco
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Alabama Vaccine Crs
Birmingham, Alabama, United States
- Bridge Hiv Crs
San Francisco, California, United States
- Columbia P&s Crs
New York, New York, United States
- New York Blood Center Crs
New York, New York, United States
- University of Rochester Vaccines To Prevent Hiv Infection Crs
Rochester, New York, United States
- Vanderbilt Vaccine (vv) Crs
Nashville, Tennessee, United States
- Seattle Vaccine and Prevention Crs
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2007
- Primary completion
- 31 Jul 2008
- Completion
- 31 Jan 2013
- Last update posted
- 14 Oct 2021
- Registered enrollment
- 17
- Registry id
- NCT00472719
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.